Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Infect Immun
1998 Dec 01;6612:5607-12. doi: 10.1128/IAI.66.12.5607-5612.1998.
Show Gene links
Show Anatomy links
The lipopolysaccharide of Bordetella bronchiseptica acts as a protective shield against antimicrobial peptides.
Banemann A
,
Deppisch H
,
Gross R
.
???displayArticle.abstract???
Resistance profiles of the two Bordetella species B. bronchiseptica and B. pertussis against various antimicrobial peptides were determined in liquid survival and agar diffusion assays. B. bronchiseptica exhibited significantly higher resistance against all tested peptides than B. pertussis. The most powerful agents acting on B. bronchiseptica were, in the order of their killing efficiencies, cecropin P > cecropin B > magainin-II-amide > protamine > melittin. Interestingly, for B. bronchiseptica, the resistance level was significantly affected by phase variation, as a bvgS deletion derivative showed an increased sensitivity to these peptides. Tn5-induced protamine-sensitive B. bronchiseptica mutants, which were found to be very susceptible to most of the cationic peptides, were isolated. In two of these mutants, the genetic loci inactivated by transposon insertion were identified as containing genes highly homologous to the wlbA and wlbL genes of B. pertussis that are involved in the biosynthesis of lipopolysaccharide (LPS). In agreement with this finding, the two peptide-sensitive mutants revealed structural changes in the LPS, resulting in the loss of the O-specific side chains and the prevalence of the LPS core structure. This demonstrates that LPS plays a major role in the resistance of B. bronchiseptica against the action of antimicrobial peptides and suggests that B. pertussis is much more susceptible to these peptides due to the lack of the highly charged O-specific sugar side chains.
Allen,
Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica.
1998, Pubmed
Allen,
Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica.
1998,
Pubmed
Allen,
The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in Bordetella pertussis.
1996,
Pubmed
Amano,
Biochemical and immunological comparison of lipopolysaccharides from Bordetella species.
1990,
Pubmed
Aspedon,
The antibacterial action of protamine: evidence for disruption of cytoplasmic membrane energization in Salmonella typhimurium.
1996,
Pubmed
Banemann,
Phase variation affects long-term survival of Bordetella bronchiseptica in professional phagocytes.
1997,
Pubmed
Beier,
In vivo characterization of the unorthodox BvgS two-component sensor protein of Bordetella pertussis.
1995,
Pubmed
Bensch,
hBD-1: a novel beta-defensin from human plasma.
1995,
Pubmed
Blay,
Antigenic polymorphism of the lipopolysaccharides from human and animal isolates of Bordetella bronchiseptica.
1997,
Pubmed
Devereux,
A comprehensive set of sequence analysis programs for the VAX.
1984,
Pubmed
Di Fabio,
Characterization of the common antigenic lipopolysaccharide O-chains produced by Bordetella bronchiseptica and Bordetella parapertussis.
1992,
Pubmed
Diamond,
Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA.
1991,
Pubmed
Ewanowich,
Invasion of HeLa 229 cells by virulent Bordetella pertussis.
1989,
Pubmed
Falkow,
The interaction of bacteria with mammalian cells.
1992,
Pubmed
Fernandez,
Susceptibilities of Bordetella pertussis strains to antimicrobial peptides.
1996,
Pubmed
Finn,
Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant.
1995,
Pubmed
Goldman,
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis.
1997,
Pubmed
Graeff-Wohlleben,
Cloning and characterization of an Mn-containing superoxide dismutase (SodA) of Bordetella pertussis.
1997,
Pubmed
Groisman,
Bacterial responses to host-defense peptides.
1996,
Pubmed
Gross,
Positive regulation of pertussis toxin expression.
1988,
Pubmed
Gueirard,
Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host.
1995,
Pubmed
Guzman,
Invasion and intracellular survival of Bordetella bronchiseptica in mouse dendritic cells.
1994,
Pubmed
Harder,
A peptide antibiotic from human skin.
1997,
Pubmed
Laemmli,
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
1970,
Pubmed
Lee,
A new assay for invasion of HeLa 229 cells by Bordetella pertussis: effects of inhibitors, phenotypic modulation, and genetic alterations.
1990,
Pubmed
Lehrer,
Antibacterial activity of microbicidal cationic proteins 1 and 2, natural peptide antibiotics of rabbit lung macrophages.
1983,
Pubmed
Lehrer,
Ultrasensitive assays for endogenous antimicrobial polypeptides.
1991,
Pubmed
Leininger,
Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin.
1992,
Pubmed
Maloy,
Structure-activity studies on magainins and other host defense peptides.
1995,
Pubmed
McCray,
Human airway epithelia express a beta-defensin.
1997,
Pubmed
Monack,
Phase variants of Bordetella bronchiseptica arise by spontaneous deletions in the vir locus.
1989,
Pubmed
Nicolas,
Peptides as weapons against microorganisms in the chemical defense system of vertebrates.
1995,
Pubmed
Parra-Lopez,
Molecular genetic analysis of a locus required for resistance to antimicrobial peptides in Salmonella typhimurium.
1993,
Pubmed
Peppler,
Two physically and serologically distinct lipopolysaccharide profiles in strains of Bordetella pertussis and their phenotype variants.
1984,
Pubmed
Rana,
Interactions between magainin 2 and Salmonella typhimurium outer membranes: effect of lipopolysaccharide structure.
1991,
Pubmed
,
Xenbase
Ray,
Variability in LPS composition, antigenicity and reactogenicity of phase variants of Bordetella pertussis.
1991,
Pubmed
Relman,
Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis.
1990,
Pubmed
Savelkoul,
Invasion of HeLa cells by Bordetella bronchiseptica.
1993,
Pubmed
Schipper,
Epithelial cell invasion and survival of Bordetella bronchiseptica.
1994,
Pubmed
Selsted,
Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes.
1984,
Pubmed
Shafer,
Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family.
1998,
Pubmed
Stainer,
A simple chemically defined medium for the production of phase I Bordetella pertussis.
1970,
Pubmed
Stibitz,
Subcellular localization and immunological detection of proteins encoded by the vir locus of Bordetella pertussis.
1991,
Pubmed
Tsai,
A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.
1982,
Pubmed
Turcotte,
Tn5-induced lipopolysaccharide mutations in Bordetella pertussis that affect outer membrane function.
1997,
Pubmed
Uhl,
Integration of multiple domains in a two-component sensor protein: the Bordetella pertussis BvgAS phosphorelay.
1996,
Pubmed
Weiss,
Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure.
1980,
Pubmed
Weiss,
Genetic analysis of phase change in Bordetella pertussis.
1984,
Pubmed
Weiss,
Virulence factors of Bordetella pertussis.
1986,
Pubmed
Woolfrey,
Human infections associated with Bordetella bronchiseptica.
1991,
Pubmed
Zhao,
Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells.
1996,
Pubmed